Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.50 |
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | NOS3 | P29474 | 4/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074503 | 1.00 | NOS1 (0.50) | NOS1NOS2NOS3ADRA1AADRA2A | |
| SCHEMBL9559207 | 0.94 | NOS1 (0.47) | NOS1NOS2NOS3ADRA1AADRA2A | |
| SCHEMBL3880710 | 0.76 | CYP19A1 (0.44) | NOS1ALDH1A1KDM4EACHE | |
| SCHEMBL1005903 | 0.76 | NOS1 (0.41) | NOS1NOS2NOS3ADRA1AADRA2A | |
| SCHEMBL3922142 | 0.75 | NOS1 (0.40) | NOS1NOS2NOS3ADRA1A | |
| SCHEMBL7502383 | 0.73 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5474778 | 0.73 | NOS1 (0.39) | NOS1NOS2NOS3ADRA1A | |
| SCHEMBL28868450 | 0.72 | HCAR3 (0.38) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL16115899 | 0.71 | NOS1 (0.44) | NOS1NOS2NOS3 | |
| SCHEMBL1012779 | 0.71 | NOS1 (0.40) | NOS1NOS2NOS3ADRA1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | CRESCENTA BIOSCIENCES (US) | 2024-11-12 | — | — | US | disclosed |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023121238-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
| CN-114173780-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| US-20220033417-A1 | THERAPEUTIC AGENTS AND USES THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| EP-3848992-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Display Co., Ltd. (KR) | 2021-07-14 | — | — | EP | disclosed |
| CN-105503699-B | Oxocarbon compound, resin composition containing the same, and filter containing the resin composition | 株式会社日本触媒 | 2021-05-11 | — | — | CN | disclosed |
| EP-3657563-A2 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Display Co., Ltd. (KR) | 2020-05-27 | — | — | EP | disclosed |
| US-10577327-B2 | Pyridine based ionic fluoride for catalyzing indole and tetrazole formation | KING ABDULAZIZ UNIVERSITY (SA) | 2020-03-03 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-8039474-B2 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-1833791-B1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1833791-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006070325-A3 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006070325-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-07-06 | — | — | WO | disclosed |
| US-6849644-B2 | Isoquinoline derivatives useful in the treatment of CNS disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | NOS1 597/4885NOS2 183/4885NOS3 231/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | NOS1 3307/4885NOS2 3315/4885NOS3 3218/4885 |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | NOS1 2112/4885NOS2 2059/4885NOS3 1668/4885 |
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, CRHR2, GRK2 | NOS1 3948/4885NOS2 3164/4885NOS3 3084/4885 |
| US-10577327-B2 | Pyridine based ionic fluoride for catalyzing indole and tetrazole formation | FLI1, ABL1, INMT | NOS1 2642/4885NOS2 2636/4885NOS3 2630/4885 |
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | FABP1, FABP5, FABP4 | NOS1 4438/4885NOS2 4693/4885NOS3 4543/4885 |
| US-20220062233-A1 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | NSUN2, RTCB, RRM2B | NOS1 3708/4885NOS2 4014/4885NOS3 3583/4885 |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | NOS1 4340/4885NOS2 4657/4885NOS3 4472/4885 |
| US-20220033417-A1 | THERAPEUTIC AGENTS AND USES THEREOF | MCL1, BCL9, RNASE1 | NOS1 3608/4885NOS2 3668/4885NOS3 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.